Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Pemetrexed in First-Line Metastatic Nonsquamous NSCLC
NCT03976323Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Feb 2024
- Countries
- 20
01
Overview
A Phase 3 trial of olaparib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Merck & Co.. Started Jun 2019; status: completed.
02
Drugs
olaparib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03976323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976323.